Episode 57 — Drug Pricing: What Trends Emerged From the 2023 Medicaid Drug Rebate Program Summit?

Not surprisingly, the Inflation Reduction Act (IRA) and its impact on the pharmaceutical industry was a key topic when manufacturers, government officials, and other stakeholders convened in Chicago for the annual Medicaid Drug Rebate Program Summit. The conference’s wide-ranging agenda spotlighted key questions and trends emerging from the Centers for Medicare and Medicaid Services’ recent activity, including the publication of the first group of drugs selected for negotiation under the IRA and the release of a proposed Medicaid regulation earlier this summer.  Representatives from the Federal Trade Commission emphasized the agency’s interest in pharmacy benefit managers, while the Office of the Inspector General explained that the IRA will be a key focus in the coming year.

In this episode of Connected with Latham, partner Chris Schott and associate Danny Machado recap their biggest takeaways from the Summit, and discuss how the IRA will continue to shape the pharmaceutical sector.

Listen here or subscribe via Apple Podcasts, Google Podcasts, Spotify, or anywhere else you listen to podcasts.